Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone

Pediatric Critical Care Medicine

Volumn 12, Issue 2, 2011, Pages

  Pedapati, Ernest V ^a   Bateman, Scot T ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Buprenorphine; children; critical care; dependence; exposure; ingestion; intensive care unit; opioid; overdose; patient education; pediatric; pediatric intensive care unit; poisoning; safety; Suboxone; Subutex; toddler; toxicology

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; INFUSION FLUID; NALOXONE;

ADOLESCENT; AGITATION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COMA; CONFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYANOSIS; DIAPHORESIS; DROWSINESS; DRUG EXPOSURE; DRUG INTOXICATION; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; HYPOXIA; INFANT; INTENSIVE CARE; INTENSIVE CARE UNIT; IRRITABILITY; LETHARGY; MALE; MEDICAL RECORD REVIEW; MIOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RESPIRATORY FUNCTION; TODDLER; TREATMENT PLANNING; UNITED STATES;

EID: 79953069744     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181f3a118     Document Type: Article

References (30)

1. Results from the 2007 National Survey on Drug Use and Health: National Findings. Rockville, MD, Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2008) NSDUH Series H-34, Department of Health and Human Services Publication No. SMA 08-4343
2. Batki SL, Kauffman JF, Marion I, et al: Med-ication-assisted treatment for opioid addic-tion in opioid treatment programs. In: Cen-ter for Substance Abuse Treatment: Treatment Improvement Protocol (TIP) Se-ries 43. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2005, DHHS Publication No. SMA 05-4048, pp 63-68
3. Department of Health (England) and the De-volved Administrations: Drug misuse and de-pendence: UK guidelines on clinical manage-ment London, UK, Department of Health (England), the Scottish Government, Welsh Assembly Government, and Northern Ireland Executive 2007
4. World Health Organization: Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. NLM classi-fication: WM 284. Geneva, Switzerland, World Health Organization, 2009
5. Connock M, Juarez-Garcia A, Jowett S, et al: Methadone and buprenorphine for the man-agement of opioid dependence: A systematic review and economic evaluation. Health Technol Assess 2007; 9:1-171, iii-iv
6. Gowing L, Farrell M, Bornemann R, et al: Substitution treatment of injecting opioid users for prevention of HIV infection. Co-chrane Database Syst Rev 2008; 16: CD004145
7. Fudala PJ, Bridge TP, Herbert S, et al: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenor-phine and naloxone. N Engl J Med 2003; 349:949-958 (Pubitemid 37064768)
8. McCance-Katz E: Emerging clinical chal-lenges in prescribing buprenorphine. SAM-HSA, Buprenorphine Summit, Washington, DC, 2008. Available at: http://buprenorphine. samhsa.gov/presentations/McCance-Katz.pdf
9. Suboxone (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets)/Subutex (bu-prenorphine HCl sublingual tablets) [pre-scribing information]. Richmond, VA, Reckitt Benckiser Pharmaceuticals, 2005
10. Walsh SL, Preston KL, Stitzer ML, et al: Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569-580 (Pubitemid 24192243)
11. Strain EC, Walsh SL, Preston KL, et al: The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacol-ogy (Berl) 1997; 129:329-338 (Pubitemid 27092996)
12. Johnson RE, Fudala PJ, Payne R: Buprenor-phine: Considerations for pain management. J Pain Symptom Manage 2005; 29:297-326
13. Bell JR, Butler B, Lawrance A, et al: Compar-ing overdose mortality associated with meth-adone and buprenorphine treatment. Drug Alcohol Depend 2009; 104:73-77
14. Smith MY, Bailey JE, Woody GE, et al: Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis 2007; 26:107-111 (Pubitemid 47367833)
15. Ciraulo DA, Hitzemann RJ, Somoza E, et al: Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol 2006; 46:179-192 (Pubitemid 43146449)
16. Bailey JE, Campagna E, Dart RC, et al: The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med 2009; 53:419-424
17. Hayes BD, Klein-Schwartz W, Doyon S: Toxicity of buprenorphine overdoses in children. Pediatrics 2008; 121:782-786
18. Bronstein AC, Spyker DA, Cantilena LR Jr, et al: 2007 Annual Report of the American As-sociation of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report Clin Toxicol (Phila) 2008; 46: 927-1057
19. Michael JB, Sztajnkrycer MD: Deadly pediat-ric poisons: nine common agents that kill at low doses. Emerg Med Clin North Am 2004; 22:1019-1050 (Pubitemid 39341170)
20. Sachdeva DK, Stadnyk JM: Are one or two dangerous? Opioid exposure in toddlers. JEmerg Med 2005; 29:77-84 (Pubitemid 40800245)
21. Substance Abuse and Mental Health Services Administration: Diversion and abuse of bu-prenorphine: A brief assessment of emerg-ing indicators (2006). Accessed June 28, 2009. Available at http://buprenorphine. samhsa.gov/ Buprenorphine-FinalReport- 12.6.06.pdf
22. Food and Drug Administration: Approved drug products with therapeutic equivalence evaluations. 29th ed. (2009). Accessed June 28, 2009. Available at: www.fda.gov/cder/orange/obannual.pdf
23. Doyon S, Klein-Schwartz W, Welsh C: Toxic-ity following buprenorphine ingestions. Ab-stract. Clin Toxicol 2005; 43:640
24. Gaulier JM, Charvier F, Monceaux F, et al: Ingestion of high-dose buprenorphine by a 4 year-old child. J Toxicol Clin Toxicol 2004; 42:993-995 (Pubitemid 40024267)
25. Maunuksela EL, Korpela R, Olkkola KT: Comparison of buprenorphine with mor-phine in the treatment of postoperative pain in children. Anesth Analg 1988; 67:233-239 (Pubitemid 18078264)
26. Maunuksela EL, Korpela R, Olkkola KT: Dou-ble-blind, multiple-dose comparison of bu-prenorphine and morphine in postoperative pain of children. Br JAnaesth 1988; 60:48-55 (Pubitemid 18053015)
27. Hamunen K, Olkkola KT, Maunuksela EL: Comparison of the ventilatory effects of mor-phine and buprenorphine in children. Acta Anaesthesiol Scand 1993; 37:449-453 (Pubitemid 23203952)
28. Olkkola KT, Leijala MA, Maunuksela EL: Paediatric ventilatory effects of morphine and buprenorphine revisited. Paediatr Anaesth 1995; 5:303-305
29. Schwarz KA, Cantrell FL, Vohra RB, et al: Suboxone (buprenorphine/ naloxone) toxicity in pediatric patients: A case report. Pediatr Emerg Care 2007; 23:651-652 (Pubitemid 47429063)
30. Geib AJ, Babu K, Ewald MB, et al: Adverse effects in children after unintentional bu-prenorphine exposure. Pediatrics 2006; 118: 1746-1751 (Pubitemid 46393828)